Axatilimab
Phase 1b/2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN/MDS Overlap or High-Risk CMML
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 52 patients (estimated)
- Sponsors
- The Ohio State University Comprehensive Cancer Center
- Collaborators
- Incyte Corporation
- Tags
- Monoclonal Antibody, CSF1R Inhibitor
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1973
- NCT Identifier
- NCT06523556
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.